46. Malignant rheumatoid arthritis Clinical trials / Disease details

Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00144534 (ClinicalTrials.gov)	June 2004	2/9/2005	Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP	An Open-label, Extension, Phase III Study to Evaluate the Long-term Safety and Efficacy of MRA in Patients With RA Who Participated in Study MRA213JP	Rheumatoid Arthritis	Drug: MRA (Tocilizumab)	Chugai Pharmaceutical	NULL	Completed	20 Years	75 Years	Both	115	Phase 3	NULL
2	NCT00144508 (ClinicalTrials.gov)	March 2003	2/9/2005	Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA)	An Open-Label, Phase III Study to Evaluate the Efficacy and Safety of MRA in Patients With RA	Rheumatoid Arthritis	Drug: MRA (Tocilizumab);Other: current treatment	Chugai Pharmaceutical	NULL	Completed	20 Years	N/A	Both	306	Phase 3	NULL
3	JPRN-JapicCTI-050016		02/09/2005	A controlled, randomized trial of MRA monotherapy in patients with rheumatoid arthritis(RA)	A controlled, randomized trial of MRA monotherapy in patients with rheumatoid arthritis(RA)	RA	Intervention name : MRA (tocilizumab) Dosage And administration of the intervention : Intravenous infusion	Chugai Pharmaceutical Co., Ltd.	NULL		20				Phase 3	NULL
4	JPRN-JapicCTI-050018		02/09/2005	Double-blind, parallel-group, controlled Phase 3 study of MRA in rheumatoid arthritis(RA)	Double-blind, parallel-group, controlled Phase 3 study of MRA in rheumatoid arthritis(RA)	RA	Intervention name : MRA (tocilizumab) Dosage And administration of the intervention : Intravenous infusion	Chugai Pharmaceutical Co., Ltd.	NULL		20	74			Phase 3	NULL